AUMENTA BIOSCIENCES, INC.

Houston, TX · Biotech · Private

Bacterial lysate immunotherapy derived from Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii for immune system augmentation

Grants
$289K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Novel Bacterially-derived Product to Enhance Immunity and Response to Immune Checkpoint Therapy$289,194
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2249BRIDGENE BIOSCIENCES, INC.——
2250OpalGenix, Inc.——
2251ProDa BioTech L.L.C.——
2252AUMENTA BIOSCIENCES, INC.——
2253General Reasoning, Inc.—$11M
2254ADDUCTNE LLC——
2255HNB Therapeutics LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.